EUVIMEDEUVIMED entdecken
Crossref

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features

Tatsuya Shimomura iD, Masaya Murakami, Kanako Kasai, Yu Imai, Yuzo Inaba, Fumihiko Urabe iD, Katsuki Muramoto, Takafumi Yanagisawa iD, Wataru Fukuokaya iD, Keiichiro Mori, Kojiro Tashiro iD, Akihiro Matsukawa und 11 weitere

The Prostate · 2026-06 · 86 (9) · 1035-1042

DOI: 10.1002/pros.70183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 17.04.2026. Verfasst von Tatsuya Shimomura und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, Phosphopyruvate Hydratase, Peptide Fragments. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuroendocrine prostate cancer (NEPC) is characterized by its aggressive biological behavior and poor prognosis, distinguishing it from prostate adenocarcinoma. Although several studies have investigated tumor markers associated with neuroendocrine differentiation and treatment outcomes, there is a lack of research focusing specifically on treatment‐naive prostate cancer. This study aims to evaluate neuroendocrine differentiation and the relationship between neuroendocrine markers (neuron‐specific enolase (NSE) and pro‐gastrin releasing peptide (pro‐GRP)) and the aggressiveness of prostate cancer at the time of diagnosis.

Methods

A total of 310 prostate cancer cases diagnosed through biopsy between October 2019 and January 2024 were analyzed. This study focused on neuroendocrine tumor markers, NSE and pro‐GRP, to evaluate the incidence of neuroendocrine differentiation. Furthermore, the relationship between these markers and tumor aggressiveness was examined, as determined by clinical T‐stage (cT), lymph node (LN) metastasis, and distant metastasis at the time of diagnosis.

Results

The incidence of positive neuroendocrine markers, defined as the presence of at least one marker exceeding the normal threshold, was 25.8%. A significant correlation was identified only between prostate‐specific antigen (PSA) and pro‐GRP ( p < 0.001). No significant relationships were observed between PSA and NSE, or between NSE and pro‐GRP ( p = 0.434 and p = 0.918, respectively). In multivariate analyses for cT ≥ 3, PSA, Ki‐67, and pro‐GRP were significant factors ( p < 0.01, p < 0.001, and p = 0.0153, respectively). For positive LN metastasis, PSA and Ki‐67 were significant ( p = 0.0178 and p < 0.0001, respectively). For positive distant metastasis, PSA, Ki‐67, and pro‐GRP were significant ( p < 0.001, p = 0.0130, and p = 0.0128, respectively).

Conclusions

Neuroendocrine tumor markers, specifically NSE and pro‐GRP, were positive in approximately 25% of treatment‐naive prostate cancer cases. While NSE did not correlate with tumor aggressiveness, pro‐GRP was associated with it and emerged as an independent factor related to tumor aggressiveness. These findings suggest that, despite both markers being linked to the same tumor type, they may exhibit distinct biological characteristics, warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorPhosphopyruvate HydratasePeptide FragmentsNeuroendocrine TumorsHumansMaleAgedMiddle AgedGastrin-Releasing PeptideProstate-Specific AntigenLymphatic MetastasisRecombinant Proteins

Stichwörter der Autor:innen

neuroendocrine differentiationneuroendocrine tumor markersneuron‐specific enolase (NSE)pro‐gastrin releasing peptide (pro‐GRP)treatment‐naive prostate cancer

Substanzen

Biomarkers, TumorPhosphopyruvate HydrataseGastrin-Releasing PeptidePeptide FragmentsProstate-Specific Antigenpro-gastrin-releasing peptide (31-98)Recombinant Proteins

Autor:innen und Institutionen

  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Fuji City General Hospital, Fuji, Japan.

ORCID-Profile: Tatsuya Shimomura, Fumihiko Urabe, Takafumi Yanagisawa, Wataru Fukuokaya, Kojiro Tashiro, Kentaro Yoshihara, Jun Miki, Takahiro Kimura

Zitieren

APA

Shimomura, T., Murakami, M., Kasai, K., Imai, Y., Inaba, Y., Urabe, F., Muramoto, K., Yanagisawa, T., Fukuokaya, W., Keiichiro Mori, Tashiro, K., Matsukawa, A., Katsumi, K., Takahashi, H., Yoshihara, K., Miyajima, K., Iwatani, K., Kayano, S., Igarashi, T., …, & Kimura, T. (2026). Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features. The Prostate, 86(9), 1035-1042. https://doi.org/10.1002/pros.70183

Vancouver

Shimomura T, Murakami M, Kasai K, Imai Y, Inaba Y, Urabe F, et al. Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features. The Prostate. 2026;86(9):1035-1042. doi:10.1002/pros.70183

BibTeX
@article{Shimomura2026,
  author = {Shimomura, Tatsuya and Murakami, Masaya and Kasai, Kanako and Imai, Yu and Inaba, Yuzo and Urabe, Fumihiko and Muramoto, Katsuki and Yanagisawa, Takafumi and Fukuokaya, Wataru and Keiichiro Mori and Tashiro, Kojiro and Matsukawa, Akihiro and Katsumi, Kota and Takahashi, Hidetsugu and Yoshihara, Kentaro and Miyajima, Keiichiro and Iwatani, Kosuke and Kayano, Sotaro and Igarashi, Taro and Tsuzuki, Shunsuke and Yamada, Hiroki and Miki, Jun and Kimura, Takahiro},
  title = {Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {9},
  pages = {1035--1042},
  doi = {10.1002/pros.70183}
}
Kostenlos starten →